Suppr超能文献

肉芽肿性多血管炎病例中的新冠病毒抗体假阳性检测

False Positive COVID-19 Antibody Test in a Case of Granulomatosis With Polyangiitis.

作者信息

Tzouvelekis Argyrios, Karampitsakos Theodoros, Krompa Anastasia, Markozannes Evangelos, Bouros Demosthenes

机构信息

First Academic Department of Respiratory Medicine, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Front Med (Lausanne). 2020 Jul 7;7:399. doi: 10.3389/fmed.2020.00399. eCollection 2020.

Abstract

Collateral damage due to 2019 novel coronavirus disease (COVID-19) represents an emerging issue. Symptoms of COVID-19 are not disease-specific. Differential diagnosis is challenging and the exclusion of other life-threatening diseases has major caveats. In the era of this pandemic, diagnosis of other life-threatening diseases might delay treatment. The Food and Drug Administration has recently authorized the first antibody-based test for COVID-19; however, RT-PCR of nasopharyngeal or oropharyngeal swabs remains the recommended test for diagnosis. We present the first report of a false positive COVID-19 antibody test in a case of Granulomatosis with Polyangiitis (GPA). Specifically, the case concerns an 82-year-old female, never smoker, who was admitted to our hospital with symptoms of fever and general fatigue that had lasted 7 days. She already had a positive IgM test for COVID-19, yet multiple RT-PCR tests had returned as negative for SARS-CoV-2. In the following days, her renal function deteriorated, while hematuria and proteinuria with active urinary sediment developed. Based on high clinical suspicion for ANCA-associated vasculitis, we performed a complete immunologic profile which revealed positive c-ANCA with elevated titers of anti-PR3. Pulses of methylprednisolone along with cyclophosphamide were applied. At day 10, treatment response was noticed as indicated by respiratory and renal function improvement. This report highlights the need for meticulous patient evaluation in order to avoid misdiagnosis in the era of COVID-19.

摘要

2019年新型冠状病毒病(COVID-19)造成的附带损害是一个新出现的问题。COVID-19的症状并非该疾病所特有。鉴别诊断具有挑战性,排除其他危及生命的疾病存在重大注意事项。在这场大流行的时代,诊断其他危及生命的疾病可能会延误治疗。美国食品药品监督管理局最近批准了首个基于抗体的COVID-19检测;然而,鼻咽或口咽拭子的逆转录聚合酶链反应(RT-PCR)仍然是推荐的诊断检测方法。我们报告了首例在肉芽肿性多血管炎(GPA)病例中出现COVID-19抗体检测假阳性的情况。具体而言,该病例是一名82岁从不吸烟的女性,因持续7天的发热和全身乏力症状入院。她的COVID-19 IgM检测已经呈阳性,但多次SARS-CoV-2的RT-PCR检测结果均为阴性。在接下来的几天里,她的肾功能恶化,同时出现血尿、蛋白尿以及活跃的尿沉渣。基于对ANCA相关性血管炎的高度临床怀疑,我们进行了全面的免疫学检查,结果显示抗蛋白酶3(PR3)滴度升高的c-ANCA阳性。应用了甲泼尼龙冲击疗法及环磷酰胺。在第10天,观察到呼吸和肾功能改善表明治疗有反应。本报告强调在COVID-19时代需要对患者进行细致评估以避免误诊。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5e3/7358541/7da2b03545cd/fmed-07-00399-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验